These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 11363554)

  • 1. Elusive HIV co-factor identified.
    AIDS Alert; 1996 Jul; 11(7):83. PubMed ID: 11363554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NIH scientists find cofactor for HIV entry. National Institutes of Health.
    James JS
    AIDS Treat News; 1996 May; (no 247):1, 6. PubMed ID: 11363488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pouncing on the chemokine receptor Chimera.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1997 Aug; 3(8):13-24. PubMed ID: 11364629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NIAID researchers identify cofactors for entry of HIV into cells. National Institute of Allergy and Infectious Diseases.
    Folkers G
    NIAID AIDS Agenda; 1996 Jun; ():1, 10-1. PubMed ID: 11363806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral entry discovery suggests new treatments.
    Smart T
    GMHC Treat Issues; 1996 May; 10(5):1-2. PubMed ID: 11363581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-2 (IL-2): a path toward functional eradication?
    Proj Inf Perspect; 1998 Dec; (26):20-1. PubMed ID: 11366494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs, new vaccines, new diseases. An interview with Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID).
    Fuller J
    Glob Issues; 1996 Nov; 1(17):10-3. PubMed ID: 12349252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New TB therapy works for HIV-positive patients.
    AIDS Alert; 1998 May; 13(5):58-9. PubMed ID: 11365414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experts clarify issues raised by combination therapy.
    AIDS Alert; 1998 May; 13(5):suppl 1-2. PubMed ID: 11365415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fauci presents NIAID strategy for HIV vaccine development. National Institute of Allergy and Infectious Diseases.
    Folkers G
    NIAID AIDS Agenda; 1996 Mar; ():1, 19. PubMed ID: 11363792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health officials argue that generalists can treat HIV.
    AIDS Alert; 1997 Sep; 12(9):104-5. PubMed ID: 11364585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs.
    Vermeire K; Schols D
    J Antimicrob Chemother; 2005 Aug; 56(2):270-2. PubMed ID: 15980096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemokine receptors: their role in human immunodeficiency virus (HIV) pathogenicity and resistance to HIV infections].
    Us D
    Mikrobiyol Bul; 2003 Jan; 37(1):75-87. PubMed ID: 12838682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly intermittent treatment: caution.
    James JS
    AIDS Treat News; 2000 Jul; (347):2-3. PubMed ID: 12170982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panels to develop standards for antiviral therapy, viral-load testing.
    AIDS Alert; 1997 Feb; 12(2):13-5. PubMed ID: 11364029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic tradeoffs in the raft-mediated entry of human immunodeficiency virus type 1 into cells.
    Lim KI; Yin J
    Biotechnol Bioeng; 2006 Feb; 93(2):246-57. PubMed ID: 16136590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of HIV-1 epitopes that induce the synthesis of a R5 HIV-1 suppression factor by human CD4+ T cells isolated from HIV-1 immunized hu-PBL SCID mice.
    Yoshida A; Tanaka R; Kodama A; Yamamoto N; Ansari AA; Tanaka Y
    Clin Dev Immunol; 2005 Dec; 12(4):235-42. PubMed ID: 16584108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency.
    Jekle A; Chow E; Kopetzki E; Ji C; Yan MJ; Nguyen R; Sankuratri S; Cammack N; Heilek G
    Antiviral Res; 2009 Sep; 83(3):257-66. PubMed ID: 19559732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.